-
Mashup Score: 1
Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@DrSteveMartin, of @EinsteinMed, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer. #lcsm #NYLung22 https://t.co/0zJSG82xgm
-
-
Mashup Score: 2
Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated NSCLC, Zosia Piotrowska, MD, MHS, told her audience at the 17th Annual New York Lung Cancers Symposium®. @ZPiotrowskaMD @MassGeneralNews #lcsm #NYLung22 https://t.co/86cdgTaarC https://t.co/Fdcs6DQcyV
-
-
Mashup Score: 1
Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC @DrSteveMartin @EinsteinMed @gotoPER #lcsm #gotoPER #NYLung22 https://t.co/9SOH1nX2Tq
-
-
Mashup Score: 0Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC - 1 year(s) ago
In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC @benlevylungdoc @hopkinskimmel @gotoPER #lcsm #NYLung22 https://t.co/ym8G7G4Oky
-
-
Mashup Score: 0
Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Targeting the ‘New Kids on the Block’: EGFR and MET Exon 20–mutant NSCLC @CatherineShuMD @columbiacancer @gotoPER #NYLung22 #lcsm https://t.co/6hs1zhiM31
-
-
Mashup Score: 0
Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC @ZPiotrowskaMD @MassGeneralNews #lcsm @gotoPER #NYLung22 https://t.co/263PbKn9Kq
-
For patients with NSCLC without driver mutations such as EGFR or ALK, immunotherapy-based regimens have become standard of care in the frontline setting. @DrSteveMartin @EinsteinMed #lcsm #NYLung22 https://t.co/bjEng8jEA7 https://t.co/70D82jIltb